

Francois Maignen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7644038/publications.pdf>

Version: 2024-02-01

13
papers

243
citations

1162367

8
h-index

1125271

13
g-index

13
all docs

13
docs citations

13
times ranked

308
citing authors

#	ARTICLE	IF	CITATIONS
1	Validation of Statistical Signal Detection Procedures in EudraVigilance Post-Authorization Data. <i>Drug Safety</i> , 2010, 33, 475-487.	1.4	73
2	Comparing access to orphan medicinal products in Europe. <i>Orphanet Journal of Rare Diseases</i> , 2019, 14, 95.	1.2	57
3	Assessing the extent and impact of the masking effect of disproportionality analyses on two spontaneous reporting systems databases. <i>Pharmacoepidemiology and Drug Safety</i> , 2014, 23, 195-207.	0.9	37
4	A conceptual approach to the masking effect of measures of disproportionality. <i>Pharmacoepidemiology and Drug Safety</i> , 2014, 23, 208-217.	0.9	17
5	Late translational research: putting forward a new model for developing new anti-cancer treatments that addresses the needs of patients and society. <i>Molecular Oncology</i> , 2019, 13, 558-566.	2.1	13
6	A mathematical framework to quantify the masking effect associated with the confidence intervals of measures of disproportionality. <i>Therapeutic Advances in Drug Safety</i> , 2017, 8, 231-244.	1.0	11
7	Modelling the Time to Onset of Adverse Reactions with Parametric Survival Distributions. <i>Drug Safety</i> , 2010, 33, 417-434.	1.4	10
8	A Case of Therapy-Related Myeloid Neoplasm in a Patient with Crohn's Disease Treated with Azathioprine. <i>Acta Haematologica</i> , 2012, 128, 1-6.	0.7	8
9	Integrating health technology assessment requirements in the clinical development of medicines: the experience from NICE scientific advice. <i>European Journal of Clinical Pharmacology</i> , 2017, 73, 297-305.	0.8	8
10	OP138 Access To Orphan Drugs In The United Kingdom And Other European Countries. <i>International Journal of Technology Assessment in Health Care</i> , 2017, 33, 64-65.	0.2	4
11	Outcomes of early health technology assessment dialogues in medicinal product development. <i>Nature Reviews Drug Discovery</i> , 2017, 16, 79-79.	21.5	2
12	Does serious consequential masking exist? An update. <i>Pharmacoepidemiology and Drug Safety</i> , 2017, 26, 727-729.	0.9	2
13	Transgenic Expression of Human Platelet Fcγ ₃ RIIA (CD32A) in Mice Does Not Affect the Thrombocytopenia Associated with WASp Deficiency. <i>Blood</i> , 2006, 108, 1106-1106.	0.6	1